Continuous Chemotherapy in Metastatic Breast Cancer
Author Information
Author(s): A.R. Dixon, L. Jackson, S.Y. Chan, R.A. Badley, R.W. Blamey
Primary Institution: City Hospital, Nottingham and Unilever Research, Sharnbrook, Bedford, UK
Hypothesis
Can a biochemical response index improve the selection of patients for continuous chemotherapy in metastatic breast cancer?
Conclusion
Using a biochemical response index to guide chemotherapy in metastatic breast cancer patients leads to longer remission durations and improved quality of life.
Supporting Evidence
- Biochemical marker changes correlated highly with clinical responses.
- Continuous chemotherapy improved remission duration and quality of life.
- 100% sensitivity and 87% specificity were observed in the biochemical index.
Takeaway
Doctors can use special blood tests to help decide if breast cancer patients should keep getting chemotherapy, which can help them feel better and live longer.
Methodology
The study evaluated a biochemical response index in 67 patients with metastatic breast cancer treated with chemotherapy, assessing their responses through various serum markers.
Potential Biases
Potential bias in patient selection and assessment methods.
Limitations
The study had a small sample size and was not a randomized controlled trial.
Participant Demographics
Median age of assessable patients was 55 years, with a range of 26-75 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website